Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesClinical Pharmacokinetics and Pharmacodynamics of Solifenacin
Clinical Pharmacokinetics, 07/06/09
Doroshyenko O et al. - Based on withdrawal rates due to adverse effects during the 52-week treatment period, solifenacin appears to have better tolerability than immediate-release oxybutynin 10-15 mg/day and IR tolterodine 4 mg/day. With regard to the pharmacokinetics of solifenacin, and for safety reasons, doses exceeding 5 mg/day are not recommended for patients with moderate hepatic impairment, patients with severe renal impairment and subjects undergoing concomitant therapy with CYP3A4 inhibitors.
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/07/09
Potential interactions between cilostazol and probucol: A two-part, single-dose, open-label study in healthy Korean male volunteers
Clinical Therapeutics, 12/07/09
Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: An in vitro study
The International Journal of Artificial Organs, 12/07/09
Sponsor
Article Search
Sponsor